PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jrsocmedLink to Publisher's site
 
J R Soc Med. 1996 June; 89(6): 315–319.
PMCID: PMC1295815

Psoriasis, T cells and autoimmunity.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Fry L. Psoriasis. Br J Dermatol. 1988 Oct;119(4):445–461. [PubMed]
  • Barker JN. The pathophysiology of psoriasis. Lancet. 1991 Jul 27;338(8761):227–230. [PubMed]
  • Bjerke JR, Krogh HK, Matre R. Characterization of mononuclear cell infiltrates in psoriatic lesions. J Invest Dermatol. 1978 Nov;71(5):340–343. [PubMed]
  • Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442–447. [PubMed]
  • de Boer OJ, van der Loos CM, Hamerlinck F, Bos JD, Das PK. Reappraisal of in situ immunophenotypic analysis of psoriasis skin: interaction of activated HLA-DR+ immunocompetent cells and endothelial cells is a major feature of psoriatic lesions. Arch Dermatol Res. 1994;286(2):87–96. [PubMed]
  • Barker JN, Karabin GD, Stoof TJ, Sarma VJ, Dixit VM, Nickoloff BJ. Detection of interferon-gamma mRNA in psoriatic epidermis by polymerase chain reaction. J Dermatol Sci. 1991 Mar;2(2):106–111. [PubMed]
  • Morganroth GS, Chan LS, Weinstein GD, Voorhees JJ, Cooper KD. Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells. J Invest Dermatol. 1991 Mar;96(3):333–340. [PubMed]
  • Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986 Apr 1;136(7):2348–2357. [PubMed]
  • Modlin RL. Th1-Th2 paradigm: insights from leprosy. J Invest Dermatol. 1994 Jun;102(6):828–832. [PubMed]
  • Saed G, Fivenson DP, Naidu Y, Nickoloff BJ. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile. J Invest Dermatol. 1994 Jul;103(1):29–33. [PubMed]
  • Kay AB, Ying S, Varney V, Gaga M, Durham SR, Moqbel R, Wardlaw AJ, Hamid Q. Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med. 1991 Mar 1;173(3):775–778. [PMC free article] [PubMed]
  • Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993 Nov;101(5):701–705. [PubMed]
  • Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, Meyer zum Büschenfelde KH, Fleischer B. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol. 1994 Feb;102(2):145–149. [PubMed]
  • Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995 Jun;32(6):982–986. [PubMed]
  • Valdimarsson H, Baker BS, Jónsdóttir I, Powles A, Fry L. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today. 1995 Mar;16(3):145–149. [PubMed]
  • Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol. 1992 Jan;128(1):39–42. [PubMed]
  • Robinson JH, Atherton MC, Goodacre JA, Pinkney M, Weightman H, Kehoe MA. Mapping T-cell epitopes in group A streptococcal type 5 M protein. Infect Immun. 1991 Dec;59(12):4324–4331. [PMC free article] [PubMed]
  • Drake CG, Kotzin BL. Superantigens: biology, immunology, and potential role in disease. J Clin Immunol. 1992 May;12(3):149–162. [PubMed]
  • Swerlick RA, Cunningham MW, Hall NK. Monoclonal antibodies cross-reactive with group A streptococci and normal and psoriatic human skin. J Invest Dermatol. 1986 Sep;87(3):367–371. [PubMed]
  • Leung DY, Walsh P, Giorno R, Norris DA. A potential role for superantigens in the pathogenesis of psoriasis. J Invest Dermatol. 1993 Mar;100(3):225–228. [PubMed]
  • Lewis HM, Baker BS, Bokth S, Powles AV, Garioch JJ, Valdimarsson H, Fry L. Restricted T-cell receptor V beta gene usage in the skin of patients with guttate and chronic plaque psoriasis. Br J Dermatol. 1993 Nov;129(5):514–520. [PubMed]
  • Chang JC, Smith LR, Froning KJ, Schwabe BJ, Laxer JA, Caralli LL, Kurland HH, Karasek MA, Wilkinson DI, Carlo DJ, et al. CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9282–9286. [PubMed]
  • Boehncke WH, Dressel D, Manfras B, Zollner TM, Wettstein A, Böhm BO, Sterry W. T-cell-receptor repertoire in chronic plaque-stage psoriasis is restricted and lacks enrichment of superantigen-associated V beta regions. J Invest Dermatol. 1995 May;104(5):725–728. [PubMed]
  • Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol. 1974 Feb;109(2):207–211. [PubMed]
  • Tomfohrde J, Silverman A, Barnes R, Fernandez-Vina MA, Young M, Lory D, Morris L, Wuepper KD, Stastny P, Menter A, et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science. 1994 May 20;264(5162):1141–1145. [PubMed]
  • Nair RP, Guo SW, Jenisch S, Henseler T, Lange EM, Terhune M, Westphal E, Christophers E, Voorhees JJ, Elder JT. Scanning chromosome 17 for psoriasis susceptibility: lack of evidence for a distal 17q locus. Hum Hered. 1995 Jul-Aug;45(4):219–230. [PubMed]
  • Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985 Sep;13(3):450–456. [PubMed]
  • Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science. 1990 Jun 15;248(4961):1349–1356. [PubMed]
  • Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest. 1994 Jul;94(1):202–209. [PMC free article] [PubMed]
  • Nickoloff BJ, Turka LA. Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes. Immunol Today. 1994 Oct;15(10):464–469. [PubMed]
  • Nickoloff BJ, Nestle FO, Zheng XG, Turka LA. T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1: a ligand for CD28. Blood. 1994 May 1;83(9):2580–2586. [PubMed]
  • Baadsgaard O, Tong P, Elder JT, Hansen ER, Ho V, Hammerberg C, Lange-Vejlsgaard G, Fox DA, Fisher G, Chan LS, et al. UM4D4+ (CDw60) T cells are compartmentalized into psoriatic skin and release lymphokines that induce a keratinocyte phenotype expressed in psoriatic lesions. J Invest Dermatol. 1990 Sep;95(3):275–282. [PubMed]
  • Weiner HL, Mackin GA, Matsui M, Orav EJ, Khoury SJ, Dawson DM, Hafler DA. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 1993 Feb 26;259(5099):1321–1324. [PubMed]
  • Nagler-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbecke GJ. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7443–7446. [PubMed]
  • Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Flow cytometric identification of proliferative subpopulations within normal human epidermis and the localization of the primary hyperproliferative population in psoriasis. J Exp Med. 1993 Oct 1;178(4):1271–1281. [PMC free article] [PubMed]
  • Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest. 1995 Jan;95(1):317–327. [PMC free article] [PubMed]
  • Strange P, Cooper KD, Hansen ER, Fisher G, Larsen JK, Fox D, Krag C, Voorhees JJ, Baadsgaard O. T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation. J Invest Dermatol. 1993 Nov;101(5):695–700. [PubMed]
  • Griffiths CE, Voorhees JJ, Nickoloff BJ. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol. 1989 Apr;20(4):617–629. [PubMed]
  • Groves RW, Allen MH, Barker JN, Haskard DO, MacDonald DM. Endothelial leucocyte adhesion molecule-1 (ELAM-1) expression in cutaneous inflammation. Br J Dermatol. 1991 Feb;124(2):117–123. [PubMed]
  • Wakita H, Takigawa M. E-selectin and vascular cell adhesion molecule-1 are critical for initial trafficking of helper-inducer/memory T cells in psoriatic plaques. Arch Dermatol. 1994 Apr;130(4):457–463. [PubMed]
  • Alexander J, Snoke K, Ruppert J, Sidney J, Wall M, Southwood S, Oseroff C, Arrhenius T, Gaeta FC, Colón SM, et al. Functional consequences of engagement of the T cell receptor by low affinity ligands. J Immunol. 1993 Jan 1;150(1):1–7. [PubMed]
  • Griffiths CE, Powles AV, Leonard JN, Fry L, Baker BS, Valdimarsson H. Clearance of psoriasis with low dose cyclosporin. Br Med J (Clin Res Ed) 1986 Sep 20;293(6549):731–732. [PMC free article] [PubMed]
  • Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, Rocher LL, Wheeler S, Hamilton TA, Parish TG, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med. 1991 Jan 31;324(5):277–284. [PubMed]
  • Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Abu-Elmagd K, Starzl TE. Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol. 1992 Jun;128(6):781–785. [PubMed]
  • Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E, Crabtree GR. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science. 1989 Dec 22;246(4937):1617–1620. [PubMed]
  • Elder JT, Hammerberg C, Cooper KD, Kojima T, Nair RP, Ellis CN, Voorhees JJ. Cyclosporin A rapidly inhibits epidermal cytokine expression in psoriasis lesions, but not in cytokine-stimulated cultured keratinocytes. J Invest Dermatol. 1993 Dec;101(6):761–766. [PubMed]
  • Poizot-Martin I, Dhiver C, Mawas C, Olive D, Gastaut JA. Are CD4 antibodies and peptide T new treatments for psoriasis? Lancet. 1991 Jun 15;337(8755):1477–1477. [PubMed]
  • Prinz J, Braun-Falco O, Meurer M, Daddona P, Reiter C, Rieber P, Riethmüller G. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet. 1991 Aug 3;338(8762):320–321. [PubMed]
  • Weinshenker BG, Bass BH, Ebers GC, Rice GP. Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. J Am Acad Dermatol. 1989 Jun;20(6):1132–1133. [PubMed]
  • Hanifin JM, Schneider LC, Leung DY, Ellis CN, Jaffe HS, Izu AE, Bucalo LR, Hirabayashi SE, Tofte SJ, Cantu-Gonzales G, et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol. 1993 Feb;28(2 Pt 1):189–197. [PubMed]
  • Griffiths TW, Griffiths CE, Voorhees JJ. Immunopathogenesis and immunotherapy of psoriasis. Dermatol Clin. 1995 Oct;13(4):739–749. [PubMed]
  • Evans RM. The steroid and thyroid hormone receptor superfamily. Science. 1988 May 13;240(4854):889–895. [PubMed]
  • Guyre PM, Girard MT, Morganelli PM, Manganiello PD. Glucocorticoid effects on the production and actions of immune cytokines. J Steroid Biochem. 1988;30(1-6):89–93. [PubMed]
  • Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci. 1993 Dec;14(12):436–441. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press